Caris Life Sciences, Inc. CAI R3KPHARMA
Company Overview
Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and artificial intelligence/machine learning algorithms. The company's molecular intelligence product portfolio includes MI Profile Platform, a whole exome sequencing (WES)/ whole transcriptome sequencing (WTS) tissue-based molecular profiling solutions; Caris Assure Platform WES/WTS blood-based molecular profiling solutions; Precision Whole Genome Platform, a whole genome sequencing (WGS) blood- and tissue-based profiling solutions; and Caris Detect, a WGS-based multi-cancer early detection solution; Caris WGS MRD a WGS and digital droplet polymerase reaction-based minimal residual disease solution; and Caris ChromoSeq, a WGS and WTS based assay for therapy selection in hematological cancers. It also offers pharma research and development services comprising laboratory delivery, strategic data, and research services to biopharmaceutical customers. The company provides its precision oncology solutions to customers, such as hospitals, institutions and patients. The company was founded in 2008 and is headquartered in Irving, Texas.
Why Investors Should Care
Generates a return on equity of 20.1%, reflecting efficient use of shareholder capital.
Revenue has grown at a 46.5% CAGR over the past five years.
Trades at a P/E of 2.6, below the sector median of 24.8.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $812.03M (+97.0% YoY); net profit $-68.09M.
- Trailing 12 Months Year-on-year growth — revenue +45.4%.
- 5-Year Trend Long-term compounding — revenue CAGR 46.5%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 46.46% |
| 1 Year: | 45.40% |
Stock Price Performance
| 1 Year: | -27.60% |
| 6 Months: | +30.63% |
| 3 Months: | +53.78% |
| 1 Month: | +9.15% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)59.34 · Neutral
P/E of 2.59 is below the sector median of 24.83 — relatively cheaper than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Strong return on equity of 20.1%.
- Compounding revenue at 46.5% over 5 years.
- Generates positive free cash flow.
CONS
- Trading 36.8% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | CAI Caris Life Sciences, Inc. R3KPHARMA | 24.82 | 2.59 | $7.01B | 0.00% | 4.52% | 20.13% | 46.46% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|
| Revenue | 100.05M | 101.62M | 120.92M | 181.40M | 216.83M | 216.17M | 263.71M |
| Operating Income | -67.01M | -60.84M | -57.95M | -17.99M | 32.64M | 5.28M | 26.93M |
| Net Income | -66.19M | -67.73M | -102.58M | -71.79M | 24.32M | -510.00K | -637.00K |
| Diluted EPS | -2.54 | -2.59 | -3.57 | -7.97 | 0.08 | 0.00 | 0.00 |
| R&D Expense | 24.79M | 27.64M | 23.07M | 25.05M | 21.62M | 31.32M | 32.36M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Revenue | 258.49M | 306.13M | 412.26M | 812.03M |
| Cost of Revenue | 178.46M | 216.82M | 233.48M | 272.87M |
| Gross Profit | 80.02M | 89.31M | 178.78M | 539.17M |
| Operating Expenses | 395.78M | 408.86M | 435.90M | 494.06M |
| Operating Income | -315.76M | -319.55M | -257.12M | 45.11M |
| EBITDA | -245.89M | -260.80M | -182.95M | 11.38M |
| Interest Expense | 26.68M | 31.61M | 50.02M | 56.85M |
| Pretax Income | -320.83M | -341.42M | -281.89M | -68.09M |
| Tax Provision | 0 | 0 | 0 | 0 |
| Net Income | -320.83M | -341.42M | -281.89M | -68.09M |
| Diluted EPS | -1.57 | -1.82 | -1.36 | -3.22 |
| R&D Expense | - | 116.88M | 113.92M | 101.58M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Total Assets | - | - | 343.73M | 1.13B |
| Total Equity | -1.70B | -2.14B | -2.50B | 577.31M |
| Cash & Equivalents | - | - | 63.95M | 796.27M |
| Long Term Debt | - | - | 319.44M | 378.82M |
| Total Liabilities | - | - | 620.92M | 548.36M |
| Current Liabilities | - | - | 165.42M | 127.14M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Operating Cash Flow | -276.10M | -245.20M | 83.16M |
| Investing Cash Flow | 214.77M | 52.93M | -16.26M |
| Financing Cash Flow | 10.13M | 200.29M | 664.99M |
| Capital Expenditure | -22.32M | -8.44M | -16.26M |
| Free Cash Flow | -298.42M | -253.64M | 66.89M |
| Share Buybacks | 0 | 0 | 113.00K |
Ratios (Annual)
Figures in %.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Gross Margin % | 31.0% | 29.2% | 43.4% | 66.4% |
| Operating Margin % | -122.2% | -104.4% | -62.4% | 5.6% |
| Net Margin % | -124.1% | -111.5% | -68.4% | -8.4% |
| ROE % | 18.8% | 15.9% | 11.3% | -11.8% |
| ROCE % | - | - | -144.2% | 4.5% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | FMR, LLC | 10.94% | 30.92M | $927.10M |
| 2 | J. H. Whitney Equity Partners VI, LLC | 3.98% | 11.26M | $337.47M |
| 3 | Coatue Management LLC | 3.47% | 9.82M | $294.40M |
| 4 | Braidwell LP | 2.92% | 8.26M | $247.52M |
| 5 | Sixth Street Partners Management Company, L.P. | 2.59% | 7.33M | $219.66M |
| 6 | PointState Capital LP | 2.42% | 6.83M | $204.73M |
| 7 | JPMORGAN CHASE & CO | 2.32% | 6.56M | $196.62M |
| 8 | Blackrock Inc. | 1.96% | 5.54M | $165.99M |
| 9 | T. Rowe Price Investment Management, Inc. | 1.80% | 5.08M | $152.27M |
| 10 | Vanguard Portfolio Management LLC | 1.71% | 4.84M | $145.24M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for CAI
Caris Life Sciences Launches New National Commercial Featuring Kevin Costner to Raise Awareness of Early Cancer Detection and Caris Detect - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxQWHp2cFdZSnRJSlppTGpEVHRyX2VnUVl3by1Hb0VmeUFWQk8zOFZYS1NTc09sRmZoTkl2dmxicVIwTFU0S2s0SWFuWTNCS3Rwd3pXaFpVY2h4Rjg0ZGQwUndRb2FOVnhEQW5zSldVMjNMQXRGbXRKX0xoLUNSQUNnX0MydEdMeWxQN2dNZF…
Could Caris Life Sciences (CAI) Be 7% Undervalued After Its Lung Cancer Research Update? - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMilAFBVV95cUxQLS1xTUxoZEk2ZDFSMDNTQm5hVERNV1BaTkpZWlY2MmpSNVBpbjBiZ01nYTBNNHVMVGxJMVp4MmEzczNzQVB5d1VlWUNEMjFkOTQ1WnZKaXJIN3lnbWViNUhRNzhWVHFYVDZLcEV5QTdGZFdWQ2JLSVBOR3R0VUs4bUZzNHY4elQzS25iT2…
Caris Life Sciences, Inc. - Common Stock (CAI) Stock Price, News, Quote & History - FinancialContent
<a href="https://news.google.com/rss/articles/CBMiWEFVX3lxTE96aTFlN0x1LXFPOUtDbHI0MGR0bmR3dVp1UE1fWGhjZGk0Rk84Q0VnbDN0ZVpEcDFaUUplLU1ZeGUyVlZTOXlTNXh3WVBIOVI4WURIcmZxbW4?oc=5" target="_blank">Caris Life Sciences, Inc. - Common Stock (CAI) S…
David Baxley Spetzler Sells 478,000 Shares of Caris Life Sciences (NASDAQ:CAI) Stock - marketbeat.com
<a href="https://news.google.com/rss/articles/CBMi2wFBVV95cUxOaFNsTDVrR05TRnZWSUlKNUo4SU9CV3JVV2tnR2g2MEMwNHlvMG5XeVN3S0N6OWlpUEJlc3JyRWdYd1N3QkNXem0zZUwwQVFKaThuRGZkWlhzbVVGMWtWMFdtbjM4UWNyYmQ3N2t4XzZRMkVzUkR6RHNOc3dReVU2cTlVS0l2bThUaVJHem…
Why Caris Life Sciences (CAI) Stock Is Up Today - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMijAFBVV95cUxQblo1Rm1SOHA5Wng2cDdnak1NdmNxUEYtTEZKdEJtRW84V21kVFYzV2FPUVdPZWs4bzYtOTNCUjRGYlVpT05fWkJoWGNqcFZPZ05feUQ2M2NLdVY5ZmVvZmFFaDVqRVR0VmVhZHlSbWVCdTVUN3hPTThzQjM5VF9neE9jaTd1elBWVzljOQ…
Caris Life Sciences (CAI) Stock Looks Undervalued On A 47% Slump - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMimgFBVV95cUxNd3VkT25zNzRGYVdWeXJCZC0xWXJCbXNyMjNUREdmOVBHeUk3WnZjaUNSRWpUVkxxcTBCWktmTl9CdmIxR1c3aUpJRkpHdGZMNUJOcllwckEyeTY4Y0V3dmNjSHc4NjlMNHd6ZlNobTJvdk9Ud1B6NFpZV3Z0Yl9ic0ZhY3c3dllMMkFaMH…
CAI — Frequently Asked Questions
What is the current share price of Caris Life Sciences, Inc. (CAI)?
As of 2026-09-19 21:16 PDT, Caris Life Sciences, Inc. (CAI) trades at $24.82 on NasdaqGS. Its 52-week range is $14.55 to $39.30.
What is the market capitalisation of CAI?
Caris Life Sciences, Inc. (CAI) has a market capitalisation of $7.01B on NasdaqGS.
What is the P/E ratio of CAI?
CAI trades at a trailing price-to-earnings (P/E) ratio of 2.59. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 11.48.
What is the return on equity (ROE) of CAI?
CAI has a return on equity (ROE) of 20.13%. Its return on capital employed (ROCE) is 4.52%.
Is CAI a good stock to buy?
This page provides a data-driven analysis of Caris Life Sciences, Inc. (CAI), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.